Advancing Pandemic and Seasonal Influenza Vaccine Preparedness and Response: Harnessing Lessons from the Efforts to Mitigate the COVID-19 Pandemic
While the world responds to the COVID-19 pandemic, novel influenza viruses continue to be a constant pandemic threat. These viruses, which could appear at any time, can lead to circumstances and ramifications similar to or worse than the current experiences resulting from the COVID-19 pandemic.
The global response to COVID-19 has pushed the boundaries on what is possible for rapid pandemic response in several areas, including vaccine research, development, manufacturing, equitable distribution, allocation, and administration. These unprecedented actions could inform and advance future pandemic and seasonal influenza vaccine preparedness efforts.
Completed
Description
With support from the Office of Global Affairs, U.S. Department of Health and Human Services, the National Academy of Medicine has launched a rapid-response initiative to explore the current state of the art and provide recommendations to improve the global design, composition, clinical trials, production, scale-up, regulatory approval, distribution of influenza vaccines, and post-approval surveillance for adverse events.
Recommendations will be issued through National Academies consensus studies on vaccine research & development; vaccine distribution & supply chains; public health interventions & countermeasures; and global coordination, partnerships, & financing.
Collaborators
Sponsors
Department of Health and Human Services
Staff
Julie Pavlin
Lead
Patricia Cuff
Lead
Janelle Winters
Lead
Hoda Soltani
Lead
Kenisha Jefferson
Lead
Ellen Schenk
Lead
Major units and sub-units
Center for Health, People, and Places
Lead
National Academy of Medicine
Lead
Health and Medicine Division
Lead
Board on Global Health
Lead
National Academy of Medicine President's Office
Lead
Health Care and Public Health Program Area
Lead